Stable faviravir oral solution preparation and preparation method thereof
阅读说明：本技术 一种稳定的法维拉韦口服溶液制剂及其制备方法 (Stable faviravir oral solution preparation and preparation method thereof ) 是由 何广卫 刘为中 苏峰 毕东辉 于 2021-07-30 设计创作，主要内容包括：本发明属于药物制剂领域,具体的涉及一种稳定的法维拉韦口服溶液制剂及其制备方法。本发明的法维拉韦口服溶液制剂包含法维拉韦和媒介物以及其他药学上可接受的辅料；所述的媒介物包括水和pH调节剂,所述pH调节剂选自磷酸及其磷酸盐、柠檬酸及其柠檬酸盐、乳酸及其乳酸盐、碳酸及其碳酸盐、氢氧化钠、氢氧化钾中的一种或几种。本发明的法维拉韦口服液体制剂主要解决了法维拉韦片剂量较大服用不方便,所采用的pH调节剂种类少、安全性能好,口感好、制备工艺简单。(The invention belongs to the field of pharmaceutical preparations, and particularly relates to a stable faviravir oral solution preparation and a preparation method thereof. The faviravir oral solution preparation comprises faviravir, a vector and other pharmaceutically acceptable auxiliary materials; the medium comprises water and a pH regulator, wherein the pH regulator is one or more selected from phosphoric acid and phosphate thereof, citric acid and citrate thereof, lactic acid and lactate thereof, carbonic acid and carbonate thereof, sodium hydroxide and potassium hydroxide. The favelavir oral liquid preparation mainly solves the problems that the administration of favelavir tablets is inconvenient due to large dosage, the adopted pH regulator has few types, good safety performance, good taste and simple preparation process.)
1. The faviravir oral solution preparation is characterized by comprising faviravir, a vector and other pharmaceutically acceptable auxiliary materials; the medium comprises water and a pH regulator, wherein the pH regulator is one or more selected from phosphoric acid and phosphate thereof, citric acid and citrate thereof, lactic acid and lactate thereof, carbonic acid and carbonate thereof, sodium hydroxide and potassium hydroxide.
2. The faviravir oral solution formulation according to claim 1, wherein the concentration of the pH adjusting agent in the liquid formulation is between 1% and 30% (w/v), preferably between 2% and 20% (w/v).
3. The faviravir oral solution formulation of claim 1 wherein the pH of the faviravir oral liquid formulation is in the range of 4.0-9.0; further, the pH range is 6.0-8.0.
4. The faviravir oral solution formulation according to claim 1, wherein the other pharmaceutically acceptable excipients include one or more of a flavoring agent, a solubilizing agent, a preservative, and an aromatic agent.
5. The faviravir oral solution preparation according to claim 4, wherein the faviravir oral solution preparation comprises the following components in percentage by weight: 3-10% (w/v) of Vilarvir, 2-15% (w/v) of pH regulator, 0.01-5% (w/v) of flavoring agent, 0.01-3% (w/v) of solubilizer, 0.01-2% (w/v) of preservative, 0.02-1% (w/v) of aromatic, and the balance of purified water; preferably, the content ratio is as follows: 4-8% (w/v) of Vilarvir, 3-10% (w/v) of pH regulator, 0.02-1% (w/v) of flavoring agent, 0.02-1% (w/v) of solubilizer, 0.02-1% (w/v) of preservative, 0.02-0.05% (w/v) of aromatic, and the balance of purified water.
6. The faviravir oral solution formulation of claim 4, wherein the flavoring agent is selected from one or more of xylitol, mannitol, sucralose, aspartame, stevioside; further, the flavoring agent is preferably xylitol and mannitol.
7. The faviravir oral solution formulation according to claim 4, wherein the solubilizer is selected from one or more of tween 80, sodium lauryl sulfate, and glycerol; further, the solubilizer is preferably tween 80.
8. The faviravir oral solution formulation of claim 4, wherein the preservative is selected from one or more of benzoic acid, sodium benzoate, methylparaben, ethylparaben, propylparaben, and potassium sorbate; further, the preservative is preferably potassium sorbate.
9. The faviravir oral solution formulation according to claim 4, wherein the flavoring agent is selected from one or more of mint flavor, strawberry flavor, banana flavor, mango flavor, grape flavor, lemon flavor, blueberry flavor, pineapple flavor, orange flavor, etc.; further, the flavoring agent is preferably selected from mint flavor and strawberry flavor.
10. A method of preparing faviravir oral liquid formulation according to any one of claims 1-9, comprising the steps of: (1) weighing the favilavir, the pH regulator and other pharmaceutically acceptable auxiliary materials according to the prescription amount;
(2) adding the faviravir with the prescription amount into a pH regulator and purified water, heating and stirring until the faviravir is completely dissolved;
(3) adding a certain amount of purified water to 50% -80% of the liquid preparation amount, adding other pharmaceutically acceptable auxiliary materials, and stirring for dissolving;
(4) and (4) determining the amount of the solution to be prepared, uniformly stirring, and filling to obtain the product.
Technical Field
The invention belongs to the field of pharmaceutical preparations, and particularly relates to a stable faviravir oral solution preparation and a preparation method thereof.
Background
Favipiravir is an oral viral RNA polymerase inhibitor that was originally developed by Toyama Chemical co., Ltd, japan, and inhibits viral replication. The drug was obtained in 2014 under the conditional approval in Japan, under the trade name Avigan. Because of its specific mechanism of action, faviravir is thought to be able to combat a variety of other RNA viruses in addition to influenza, such as HIV, yellow fever, SARS, ebola, and others. Avigan Tablets 200 mg/tablet 100 Tablets/bottle were determined as reference formulation according to "selection and determination procedure for reference formulation for chemical imitation pharmaceuticals". The reference formulation was 200 mg/tablet, 8.7mm biconvex round film coated tablet.
Single dose, multi-dose pharmacokinetic studies were conducted in healthy subjects, special populations and patients to study the pharmacokinetic properties of valavir. Generally, the faviravir is well absorbed by mouth and has high bioavailability. In healthy male subjects in japan (n ═ 100), faviravir was administered orally in 2400 mg single doses of CmaxAnd the mean values of AUC values were 92.17. mu.g/mL and 1297.56. mu.g-h/mL, respectively, median TmaxAnd average half-lives of 3 and 4.5 hours, respectively. Faviravir 400 mg (bid) multiple dosing, day 8CmaxAnd the mean values of AUC values were 43.83. mu.g/mL and 244.31. mu.g.h/mL, respectively, median TmaxAnd average half-life values of 0.6 and 5.2 hours, respectively.
Faviravir is soluble in water, and the solubility of faviravir in aqueous media (pH 1.2-6.8) is about 10 mg/mL. However, the dose of faviravir is very large, and is taken twice a day, 1600mg each time, twice a day for 2 to 5 days, 600mg each time, and the dosage of tablets is large. Therefore, it is very important to increase the solubility of faviravir in liquid formulations. CN111249229A (Favilavir injection patent) adopts sulfobutyl ether-beta-cyclodextrin sodium and contains an alkali regulator to improve the solubility of Favilavir, the preparation technology is more complex, is not beneficial to industrial production, has limited effect on the improvement of the solubility, has lower patient compliance of the injection and larger dosage, and has no obvious advantages compared with oral solution.
Disclosure of Invention
Aiming at the problems in the prior art, the solubility of the faviravir in an aqueous medium is low, and the invention adopts the pH regulator to prepare the faviravir oral liquid preparation with good taste and simple preparation process, thereby having obvious clinical advantages.
The faviravir oral solution preparation provided by the invention comprises faviravir, a vector and other pharmaceutically acceptable auxiliary materials; the medium comprises water and a pH regulator, wherein the pH regulator is selected from one or more of phosphoric acid and phosphate thereof, citric acid and citrate thereof, lactic acid and lactate thereof, carbonic acid and carbonate thereof, sodium hydroxide and potassium hydroxide; further, the pH regulator is preferably sodium carbonate and/or disodium hydrogen phosphate.
Further, the concentration of the pH adjusting agent in the liquid preparation is 2% to 30% (w/v), and the concentration is preferably 5% to 20% (w/v).
Further, the pH range of the faviravir oral liquid preparation is 4.0-9.0; further, the pH range is 6.0-8.0.
Further, the faviravir oral liquid preparation is preferably an oral solution, syrup or suspension.
Further, the compound preparation is characterized in that the other pharmaceutically acceptable auxiliary materials comprise one or more of a flavoring agent, a solubilizer, a preservative and an aromatic.
The faviravir oral solution preparation comprises the following components in percentage by weight: 3-10% (w/v) of Vilarvir, 2-15% (w/v) of pH regulator, 0.01-5% (w/v) of flavoring agent, 0.01-3% (w/v) of solubilizer, 0.01-2% (w/v) of preservative, 0.02-1% (w/v) of aromatic, and the balance of purified water; preferably, the content ratio is as follows: 4-8% (w/v) of Vilarvir, 3-10% (w/v) of pH regulator, 0.02-1% (w/v) of flavoring agent, 0.02-1% (w/v) of solubilizer, 0.02-1% (w/v) of preservative, 0.02-0.05% (w/v) of aromatic, and the balance of purified water.
Further, the flavoring agent is selected from one or more of xylitol, mannitol, sucralose, aspartame and stevioside; further, the flavoring agent is preferably xylitol and mannitol.
Further, the solubilizer is selected from one or more of tween 80, sodium dodecyl sulfate and glycerol; further, the solubilizer is preferably tween 80.
Further, the preservative is characterized by being selected from one or more of benzoic acid, sodium benzoate, methyl hydroxybenzoate, ethylparaben, propyl hydroxybenzoate and potassium sorbate; further, the preservative is preferably potassium sorbate.
Further, the flavoring agent is characterized in that the flavoring agent is selected from one or more of mint essence, strawberry essence, banana essence, mango essence, grape essence, lemon essence, blueberry essence, pineapple essence, orange essence and the like; further, the flavoring agent is preferably selected from mint flavor and strawberry flavor.
The invention also provides a preparation method of the faviravir oral liquid preparation, which is characterized by comprising the following steps: (1) weighing the favilavir, the pH regulator and other pharmaceutically acceptable auxiliary materials according to the prescription amount;
(2) adding the faviravir with the prescription amount into a pH regulator and purified water, heating and stirring until the faviravir is completely dissolved;
(3) adding a certain amount of purified water to 50% -80% of the liquid preparation amount, adding other pharmaceutically acceptable auxiliary materials, and stirring for dissolving;
(4) and (4) determining the amount of the solution to be prepared, uniformly stirring, and filling to obtain the product.
Has the advantages that:
the invention relates to a favelavir oral liquid preparation, which mainly solves the problems of large specifications of the favelavir and large dosage of tablets. The favelavir oral liquid preparation has the advantages of small using amount of the solubilizer, good taste and simple preparation process.
Detailed Description
The present invention will be described in further detail with reference to specific embodiments. It should be emphasized that: the following description is merely exemplary in nature and is in no way intended to limit the scope of the invention or its application.
Example 1
The formula proportion is as follows:
composition (I)
Concentration of
Favilavir
100kg
Potassium sorbate
5kg
Sodium bicarbonate
80kg
Citric acid sodium salt
40kg
Tween 80
7kg
Xylitol, its preparation method and use
2kg
Mannitol
2.5kg
Mint essence
1.5kg
Purifying the water to
2000L
The preparation process comprises the following steps:
(1) weighing the formula amounts of faviravir, potassium sorbate, sodium bicarbonate, sodium citrate, tween 80, xylitol, mannitol and mint essence;
(2) adding the formula amount of faviravir, sodium bicarbonate and sodium citrate into about 500L of water, and stirring until the faviravir is completely dissolved;
(3) adding a certain amount of purified water to about 1000L, adding potassium sorbate, tween 80, xylitol, mannitol and mint essence, and stirring for dissolving;
(4) and (5) fixing the volume to 2000L, uniformly stirring, and filling to obtain the product.
Example 2
The formula proportion is as follows:
composition (I)
Concentration of
Favilavir
100kg
Sodium benzoate
3.5kg
Disodium hydrogen phosphate
75kg
Sodium dodecyl sulfate
5kg
Xylitol, its preparation method and use
3kg
Pineapple essence
3kg
Purifying the water to
1000L
The preparation process comprises the following steps:
(1) weighing the Favilavir, sodium benzoate, disodium hydrogen phosphate, sodium dodecyl sulfate, xylitol and pineapple essence according to the prescription amount;
(2) adding the Faviravir and the disodium hydrogen phosphate into water of about 500L according to the prescription amount, and stirring until the Faviravir is completely dissolved;
(3) adding a certain amount of purified water to about 1000L, adding sodium benzoate, sodium dodecyl sulfate, xylitol and pineapple essence, stirring and dissolving;
(4) and (5) fixing the volume to 1000L, uniformly stirring, and filling to obtain the product.
Example 3
The formula proportion is as follows:
composition (I)
Concentration of
Favilavir
100kg
Nipagin methyl ester
2kg
Sodium carbonate
55kg
Sodium dodecyl sulfate
5kg
Sorbitol
5kg
Orange essence
5kg
Purifying the water to
2000L
The preparation process comprises the following steps:
(1) weighing Favilavir, methyl paraben, sodium carbonate, sodium dodecyl sulfate, sorbitol and orange essence according to the prescription amount;
(2) adding faviravir and sodium carbonate in a prescription amount into about 500L of water, and stirring until the faviravir is completely dissolved;
(3) adding a certain amount of purified water to about 1000L, adding methyl hydroxybenzoate, sodium dodecyl sulfate, sorbitol and orange essence, stirring and dissolving;
(4) and (5) fixing the volume to 2000L, uniformly stirring, and filling to obtain the product.
Example 4
The formula proportion is as follows:
the preparation process comprises the following steps:
(1) weighing the formula amounts of faviravir, benzoic acid, sodium hydroxide, sodium dihydrogen phosphate, sucralose and blueberry essence;
(2) adding the formula amounts of faviravir, sodium hydroxide and sodium dihydrogen phosphate into about 500L of water, and stirring until the faviravir is completely dissolved;
(3) adding a certain amount of purified water to about 800L, adding benzoic acid, sucralose and blueberry essence, and stirring for dissolving;
(4) and (5) fixing the volume to 2000L, uniformly stirring, and filling to obtain the product.
Example 5
The formula proportion is as follows:
composition (I)
Concentration of
Favilavir
100kg
Glycerol
15kg
Sodium lactate
25kg
Disodium hydrogen phosphate
30kg
Acesulfame potassium
3.5kg
Banana essence
2kg
Purifying the water to
2000L
The preparation process comprises the following steps:
(1) weighing Favilavir, glycerol, sodium lactate, disodium hydrogen phosphate, acesulfame potassium and banana essence according to the formula amount;
(2) adding the formula amounts of faviravir, sodium lactate and disodium hydrogen phosphate into about 500L of water, and stirring until the faviravir is completely dissolved;
(3) adding a certain amount of purified water to about 1000L, adding glycerol, acesulfame potassium and banana essence, stirring and dissolving;
(4) and (5) fixing the volume to 2000L, uniformly stirring, and filling to obtain the product.
Example 6
The formula proportion is as follows:
composition (I)
Concentration of
Favilavir
100kg
Glycerol
15kg
Malic acid sodium salt
45kg
Sodium benzoate
2kg
Sucralose
3kg
Mint essence
2kg
Purifying the water to
2000L
The preparation process comprises the following steps:
(1) weighing Favilavir, glycerol, sodium malate, sodium benzoate, sucralose and mint essence according to the prescription amount;
(2) adding faviravir and sodium malate in a prescription amount into about 800L of water, and stirring until the faviravir is completely dissolved;
(3) adding a certain amount of purified water to about 1000L, adding glycerol, sodium benzoate, sucralose and peppermint essence, and stirring for dissolving;
(4) the volume is determined to 2000L, the mixture is stirred evenly, after standing for 24h, part of solid is separated out at the bottom of the tank and can not be dissolved completely.
Example 7
The formula proportion is as follows:
composition (I)
Concentration of
Favilavir
100kg
Benzoic acid
2kg
Sodium acetate
50kg
Tween 80
7kg
Sucralose
4kg
Pineapple essence
2kg
Purifying the water to
2000L
The preparation process comprises the following steps:
(1) weighing Favilavir, benzoic acid, sodium acetate, Tween 80, sucralose and pineapple essence according to the prescription amount;
(2) adding faviravir and sodium acetate in a prescription amount into about 600L of water, and stirring until the faviravir is completely dissolved;
(3) adding a certain amount of purified water to about 1200L, adding benzoic acid, tween 80, sucralose and pineapple essence, and stirring for dissolving;
(4) metering to volume of 2000L, stirring, and canning.
Test example 1 evaluation of taste
The taste evaluation results are based on 20 healthy subjects, have strong resolving power and high sensitivity on color, fragrance and taste, are rinsed with warm water before sensory evaluation to keep the oral cavity fresh, the evaluation standard is acceptable at 6 points and is full of 10 points, and the specific sensory evaluation results are shown in table 1.
TABLE 1 evaluation results of mouthfeel of examples 1 to 7
The samples of examples 1-5 and example 7 have acceptable mouthfeel, the sample of example 2 has optimal mouthfeel, different flavoring agents and aromatics can improve the taste of the faviravir oral liquid preparation, and the auxiliary materials do not influence the drug effect of the faviravir, so that the compliance of the faviravir oral liquid preparation is improved. However, the taste of example 6 was not acceptable to the subjects, which indicates that sodium malate, when used as a pH adjuster, could not be applied to faviravir oral liquid preparations, resulting in precipitation of a portion of solids, thereby also affecting the taste.
Test example 2 stability study
Stability studies the stability of the solution systems was compared by comparing the results of the content measurements of the different examples based on a 6 month stability study experiment (accelerated conditions, sample seal placed at 40 ℃ RH 75%).
Table 2 results of stability studies of examples 1-7
The results of the content measurement of the samples of examples 1-5 accelerated for 6 months are all within limits, which indicates that the stability of the oral liquid preparation can meet the requirements when a plurality of types of pH regulators are used in the oral liquid preparation of faviravir. The sample in example 3 has the highest content, which indicates that the stability of the faviravir oral liquid preparation is the best when sodium carbonate is used as a pH regulator; however, the content of the sample in example 7 is remarkably reduced, which indicates that the stability of the faviravir oral liquid preparation is difficult to meet the preparation requirements, and sodium acetate is not suitable for being used as a pH regulator.
Finally, the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting, although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all the technical solutions of the present invention should be covered in the claims of the present invention.